Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company specializing in gastrointestinal (GI) disease treatments, has recently disclosed the pricing details of its underwritten public offering. The company aims to raise gross proceeds of up to $30 million through this offering, with an initial upfront funding of approximately $7.5 million. The offering is being led by Nantahala Capital Management, along with the participation of other fundamental investors. This substantial funding will further support Evoke Pharma’s development and commercialization plans for its key product, GIMOTI (metoclopramide) nasal spray.
GIMOTI nasal spray is a novel therapeutic solution for the treatment of various GI diseases. It is specifically designed to address gastroparesis symptoms in adult women, including nausea and vomiting. By offering a non-oral alternative, GIMOTI has the potential to revolutionize the treatment landscape for patients suffering from this debilitating condition. Evoke Pharma’s focused approach in the GI space positions them as a key player in addressing unmet medical needs and providing effective solutions.
The underwritten public offering brings a ray of hope for Evoke Pharma, as the company has suffered a challenging period marked by a decline in share price. During the first quarter of 2024, Evoke Pharma witnessed a significant drop in its shares, amounting to -27.18%. This decline has been reflected in the company’s financial performance, as it has recorded a net loss of $-8 million over the course of 12 months ending in the third quarter of 2023. Such figures contribute to a negative return on investment (ROI) of -97.95%. These numbers highlight the urgency for Evoke Pharma to secure substantial funding to support its ongoing operations and drive growth.
The participation of Nantahala Capital Management and other prominent investors in the underwritten offering is a testament to Evoke Pharma’s potential and the belief in the company’s ability to deliver on its promises. These investments will not only provide the much-needed financial boost but also serve as an endorsement of the innovation and potential of GIMOTI nasal spray.
Evoke Pharma’s strategic decision to embark on an underwritten public offering signifies a turning point for the company. With the aim of raising up to $30 million, this funding will facilitate critical milestones, including further clinical development, regulatory approvals, and marketing efforts for GIMOTI nasal spray. The offering is anticipated to generate substantial interest among investors who recognize the immense market potential of Evoke Pharma’s product portfolio.
As Evoke Pharma continues to advance its operations and establish itself as a leading player in the GI therapeutics space, the successful pricing of the underwritten public offering is a significant step forward. The funding secured from this offering will undoubtedly contribute to the company’s resurgence, enabling it to overcome the challenges faced and bring innovative solutions to patients suffering from GI diseases, particularly those living with gastroparesis.
Comments